Literature DB >> 20564390

CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.

Robert C Bast1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20564390      PMCID： PMC2988470          DOI： 10.1002/cncr.25203

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  12 in total

1.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; Moune Jabre-Raughley; Amy K Brown; Katina M Robison; M Craig Miller; W Jeffery Allard; Robert J Kurman; Robert C Bast; Steven J Skates
Journal:  Am J Obstet Gynecol       Date:  2010-05-14       Impact factor: 8.661

2.  Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.

Authors:  Antonio Santillan; Ruchi Garg; Marianna L Zahurak; Ginger J Gardner; Robert L Giuntoli; Deborah K Armstrong; Robert E Bristow
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

3.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

Authors:  I Jacobs; D Oram; J Fairbanks; J Turner; C Frost; J G Grudzinskas
Journal:  Br J Obstet Gynaecol       Date:  1990-10

4.  The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer.

Authors:  Patricia A Parker; Andrzej Kudelka; Karen Basen-Engquist; John Kavanagh; Janet de Moor; Lorenzo Cohen
Journal:  Gynecol Oncol       Date:  2005-10-20       Impact factor: 5.482

5.  Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.

Authors:  James L Wilder; Edward Pavlik; John M Straughn; Tyler Kirby; Robert V Higgins; Paul D DePriest; Frederick R Ueland; Richard J Kryscio; Ronald J Whitley; John van Nagell
Journal:  Gynecol Oncol       Date:  2003-05       Impact factor: 5.482

6.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

Authors:  G J Rustin; A E Nelstrop; M K Tuxen; H E Lambert
Journal:  Ann Oncol       Date:  1996-04       Impact factor: 32.976

7.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

8.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.

Authors:  J M Niloff; R C Bast; E M Schaetzl; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1985-04-01       Impact factor: 8.661

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

Review 10.  The CA 125 tumour-associated antigen: a review of the literature.

Authors:  I Jacobs; R C Bast
Journal:  Hum Reprod       Date:  1989-01       Impact factor: 6.918
View more
  30 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Alessia Aloisi; Patrizio Damiani; Ludovico Muzii; Giuseppe Scaletta; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Tumour Biol       Date:  2012-08-09

3.  Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.

Authors:  John A Martignetti; Olga Camacho-Vanegas; Nolan Priedigkeit; Catalina Camacho; Elena Pereira; Li Lin; Leopold Garnar-Wortzel; Dagny Miller; Bojan Losic; Hardik Shah; Jun Liao; Jian Ma; Pratik Lahiri; Mark Chee; Eric Schadt; Peter Dottino
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 4.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

5.  Serum endocan levels in endometrial and ovarian cancers.

Authors:  Esra Laloglu; Yakup Kumtepe; Hulya Aksoy; Emsal Pınar Topdagi Yilmaz
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

Review 6.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 7.  Molecular approaches to personalizing management of ovarian cancer.

Authors:  R C Bast
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

Review 8.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

9.  Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data.

Authors:  Jason E McDermott; Jing Wang; Hugh Mitchell; Bobbie-Jo Webb-Robertson; Ryan Hafen; John Ramey; Karin D Rodland
Journal:  Expert Opin Med Diagn       Date:  2013-01

10.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.